



Thai Plaspac

Superior 2023 outlook; substantial scope for future growth

Fast-growing demand for consumer-linked packaging and acquisitions set the scene for sustained long-term profit growth. And there's scope for upside to our forecasts and valuation from future new investments. We have re-initiated coverage of TPAC with a BUY call.

Consumer-linked plastic packaging provider...strong barrier to entry

TPAC is Thailand's leading rigid plastic packaging solutions provider. Its focus is everyday essential consumer categories (food & beverage, pharmaceuticals & personal care, and industrial & homecare). These categories require stringent hygiene standards—an implicit barrier to market entry that buttresses customer loyalty. TPAC has more than 1,500 clients across 50 countries, so its revenue base is broad and it isn't exposed to any significant customer concentration risk.

Substantial market opportunities for future growth

The company has expanded its footprint significantly over the past seven years from its Thailand base to India, the UAE, and Malaysia, which are fast-growing markets for FMCGs and pharmaceuticals. TPAC is strategically focused on industry niches for rigid plastic packaging in each country where it has a presence. Because these markets are expanding fairly rapidly, we see substantial growth opportunities going forward. The firm plans to expand its market shares in these countries through organic and inorganic expansion, new product development, and by building its customer base. Our sensitivity analysis suggests that for every 1% that TPAC's mean market share rises, its earnings would beat our forecasts by 7% for 2024 and by 5%, on average, for the long-term.

Expansive earnings profile and a strong balance sheet

Similarly to many other companies that operate in multiple jurisdictions, TPAC encountered cost inflation pressures in 2022, which squeezed its gross margin. GM was slimmest in 2Q22, then recovered QoQ, 3Q22-1Q23. The drivers were procurement cost savings and its ability to pass through cost increases to customers. Despite a slimmer gross margin, TPAC still delivered YoY core profit growth for 2022, led by top-line expansion (both organic volume growth and sales by recently-acquired subsidiaries).


Premised on greater sales volume to be brought about by broadly improving demand, a full-year contribution by Skypet, and a fatter GM (easing cost pressures), we expect TPAC to deliver 2023 core earnings of Bt522m, spectacular YoY growth of 75.7%. Looking further ahead, our model points to a 2024-25 core profit CAGR of 10.6%. And there's scope for upside to our revenue and earnings projections from new investments—greenfield and acquisitions. TPAC's balance sheet looks set to remain strong going forward. Hence, the company should have ample debt headroom to fund future organic investments and acquisitions.

July 21, 2023

Sector: Packaging NEUTRAL Rating: BUY

Target Price: Bt22.00 Price (Jul 20, 2023): Bt16.50

Price chart



Key statistics

Market cap	Bt5.4bn	USD0.2bn
12-mth price range	Bt12.0/Bt18.4	
12-mth avg daily volume	Bt2m	USD0.0m
# of shares (m)	327	
Est. free float (%)	21.0	
Foreign limit (%)	100.0	

Financial summary

FY Ended 31 Dec	2022	2023E	2024E	2025E	
Revenues (Btm)	6,997	7,183	7,665	8,108	
Net profit (Btm)	319	522	604	638	
EPS (Bt)	0.98	1.60	1.85	1.95	
EPS growth (%)	+108.5%	+63.6%	+15.8%	+5.7%	
Core profit (Btm)	297	522	604	638	
Core EPS (Bt)	0.91	1.60	1.85	1.95	
Core EPS growth (%)	+2.7%	+75.7%	+15.8%	+5.7%	
PER (x)	14.3	10.3	8.9	8.4	
PBV (x)	1.8	1.8	1.6	1.4	
Dividend (Bt)	0.3	0.5	0.6	0.6	
Dividend yield (%)	2.1	2.9	3.4	3.6	
ROE (%)	14.7	21.5	21.1	19.3	

CG / CAC Anti-Corruption Certification



Suppata Srisuk Securities Fundamental Investment Analyst suppata@bualuang.co.th +66 2 618 1343

Please see final page for additional important disclosures. Bualuang Securities Public Company Limited ("BLS") is a foreign broker-dealer unregistered in the USA. BLS research is prepared by research analysts who are not registered in the USA. BLS research is distributed in the USA pursuant to Rule 15a-6 of the Securities Exchange Act of 1934.




. .

RESEARCH

TPAC: Financial Tables – Year

	2020	2021	2022	2023E	2024E
PROFIT & LOSS (Btm) Revenue	3,983	5,194	6,997	7,183	7,665
Cost of sales and services	(3,025)	(4,190)	(5,841)	(5,714)	(6,060)
Gross profit	957	1,004	1,156	1,469	1,606
SG&A	(473)	(535)	(669)	(687)	(733)
EBIT	485	469	487	782	873
Interest expense	(105)	(137)	(161)	(158)	(145)
Other income/exp.	51	59	77	85	93
EBT	430	390	404	709	821
Corporate tax	(83)	(78)	(75)	(132)	(153)
After-tax net profit (loss)	347	312	328	577	668
Minority interest	(31)	(22)	(31)	(55)	(64)
Equity earnings from affiliates	0 6	0 (136)	0 22	0 0	0 0
Extra items Net profit (loss)	322	153	319	522	604
Reported EPS	0.99	0.47	0.98	1.60	1.85
Fully diluted EPS	0.99	0.47	0.98	1.60	1.85
Core net profit	316	289	297	522	604
Core EPS	0.97	0.89	0.91	1.60	1.85
EBITDA	856	955	1,047	1,308	1,439
KEY RATIOS					
Revenue growth (%)	6.0	30.4	34.7	2.7	6.7
Gross margin (%)	24.0	19.3	16.5	20.5	20.9
EBITDA margin (%)	21.5	18.4	15.0	18.2	18.8
Operating margin (%)	12.2	9.0	7.0	10.9	11.4
Net margin (%)	8.1	2.9	4.6	7.3	7.9
Core profit margin (%)	7.9	5.6	4.2	7.3	7.9
ROA (%)	7.1	2.6	4.4	6.9	7.8
ROCE (%)	8.4	3.1	5.5	8.8	9.8
Asset turnover (x)	0.9 1.3	0.9 1.3	1.0 1.1	1.0 1.1	1.0 1.1
Current ratio (x)	1.0	1.3	1.1	1.0	0.8
Gearing ratio (x) Interest coverage (x)	4.6	3.4	3.0	5.0	6.0
	1.0	0.1	0.0	0.0	0.0
BALANCE SHEET (Btm)	196	394	287	264	250
Cash & Equivalent Accounts receivable	826	1,239	1,373	1.409	1,504
Inventory	416	579	536	550	587
PP&E-net	1,476	2,139	2,342	2,501	2,428
Other assets	1,686	2,677	2,701	2,772	2,959
Total assets	4,723	7,127	7,404	7,667	7,909
Accounts payable	359	619	602	618	660
ST debts & current portion	764	1,021	1,377	1,403	1,472
Long-term debt	1,264	2,155	1,898	1,664	1,279
Other liabilities	166	725	867	890	950
Total liabilities	2,603	4,643	4,828	4,661	4,451
Paid-up capital	327	327	327	327 1,027	327 1,027
Share premium	1,027 945	1,027 714	1,027 947	1,373	1,821
Retained earnings Shareholders equity	2,062	2,133	2,210	2,636	3,084
Minority interests	59	350	367	370	374
Total Liab.&Shareholders' equity	4,723	7,127	7,404	7,667	7,909
CASH FLOW (Btm)		,			,
Net income	353	153	319	522	604
Depreciation and amortization	321	428	482	441	473
Change in working capital	(96)	(653)	(95)	(86)	(222)
FX, non-cash adjustment & others	184	Ó	Ó	Ó	Ó
Cash flows from operating activities	762	(72)	706	877	855
Capex (Invest)/Divest	(309)	(1,091)	(686)	(600)	(400)
Others	67	0	0	0	0
Cash flows from investing activities	(242)	(1,091)	(686)	(600)	(400)
Debt financing (repayment)	283	1,149	99	(208)	(316)
Equity financing	0 (41)	(295)	(95)	0 (06)	0 (157)
Dividend payment	· · /	(385)	(85)	(96)	(157)
Others Cash flows from financing activities	67 242	0 1,359	0 (127)	0 (300)	0 (469)
Cash flows from financing activities Net change in cash	762	1,359	(127)	(23)	(409)
_			. ,		
Free cash flow (Btm)	453	(1,162)	21	277	455
Key assumptions	2020	2021	2022	2023E	2024E
Sales volume (kt)	53,484	63,881	72,465	70,135	75,125
Overall utilization rate	70%	77%	70%	72%	73%






Profit margins



Capital expenditure Capex (Bt,bn) Bt,bn % Capex / Net PPE (%) 60 5 50 4 40 3 30 2 20 1 10 0 0 18 19 20 21 22 23E 24E

Debt serviceability




Dividend payout





TPAC: Financial Tables – Quarter

QUARTERLY PROFIT & LOSS (Btm)	4Q20	1Q21	2Q21	3Q21	4Q21
Revenue	982	1,089	1,138	1,397	1,570
Cost of sales and services	(752)	(815)	(926)	(1,147)	(1,301)
Gross profit	230	274	212	249	269
SG&A	(130)	(120)	(125)	(148)	(143)
EBIT	99	154	87	102	126
Interest expense	(26)	(26)	(30)	(38)	(44)
Other income/exp.	15	13	9	16	21
EBT	88	141	66	80	103
Corporate tax	(22)	(25)	(11)	(19)	(23)
After-tax net profit (loss)	66	116	55	61	80
Minority interest	(3)	(4)	(5)	(6)	(7)
Equity earnings from affiliates	0	Ó	Ó	0	Ó
Extra items	0	(132)	0	(4)	(0)
Net profit (loss)	63	(20)	51	50	72
Reported EPS	0.19	(0.06)	0.16	0.15	0.22
Fully diluted EPS	0.19	(0.06)	0.16	0.15	0.22
Core net profit	63	112	51	55	72
Core EPS	0.19	0.34	0.16	0.17	0.22
EBITDA	175	237	177	213	270
KEY RATIOS					
Gross margin (%)	23.4	25.1	18.7	17.9	17.1
EBITDA margin (%)	17.8	21.8	15.6	15.2	17.2
Operating margin (%)	10.1	14.1	7.7	7.3	8.0
Net margin (%)	6.5	(1.8)	4.5	3.6	4.6
Core profit margin (%)	6.4	10.2	4.5	3.9	4.6
BV (Bt)	6.5	6.8	6.7	7.5	7.6
ROE (%)	12.3	(3.8)	10.1	10.2	13.6
ROA (%)	5.3	(1.7)	3.4	2.9	4.0
Current ratio (x)	1.3	1.4	1.2	1.2	1.3
Gearing ratio (x)	1.0	0.9	1.5	1.4	1.3
Interest coverage (x)	3.8	5.9	2.9	2.7	2.9
QUARTERLY BALANCE SHEET (Btm)					
Cash & Equivalent	196	243	422	291	394
Accounts receivable	826	911	991	1,162	1,239
Inventory	416	517	552	641	579
PP&E-net	1,476	1,542	2,132	2,237	2,139
Other assets	1,686	1,736	2,565	2,660	2,677
Total assets	4,723	5,020	6,796	7,253	7,127
Accounts payable	359	344	521	562	619
ST debts & current portion	764	877	1,079	1,327	1,021
Long-term debt	1,264	1,191	2,282	2,162	2,155
Other liabilities	166	328	637	677	725
Total liabilities	2,603	2,799	4,601	4,812	4,643
Paid-up capital	327	327	327	327	327
Share premium	1,027	1,027	1,027	1,027	1,027
Retained earnings	945	926	607	642	714
Shareholders equity	2,062	2,155	1,870	2,097	2,133
				,	
Minority interests	59	66	326	344	350




Company profile

Thai Plaspac Plc (TPAC) designs and manufactures rigid plastic packaging for clients in the food & beverage, FMCG, pharmaceutical, personal hygiene, and homecare industries. TPAC's packaging solutions use a selected range of plastic polymers that are all recyclable and/or made from recycled materials. It has a total of 16 production facilities in four countries—India (9), Thailand (4), Malaysia (1), and the United Arab Emirates (2).

BUALUANG SECURITIES

Outlook

Consumer-linked plastic packaging provider: TPAC is Thailand's leading rigid plastic packaging solutions provider. Its focus is everyday essential consumer categories—food & beverages (F&B) (78% of 1Q23 sales), pharmaceuticals & personal hygiene products (14%), and industrial & homecare (8%). Demand in these areas has proved resilient to the vagaries of the economic cycle. Moreover, most of the categories require stringent hygiene standards, which serve as an implicit barrier to market entry, buttressing customer loyalty. TPAC has more than 1,500 clients across 50 countries—global FMCG and pharmaceutical brands, leading Thai FMCG makers, and a range of small customers—so its revenue base is broad and it isn't exposed to any significant customer concentration risk.




Source: Company data


Substantial market opportunities for future growth: The company has expanded its footprint significantly over the past seven years from its Thailand base to India, the UAE, and Malaysia, which are fast-growing markets for FMCGs and pharmaceuticals. TPAC focuses on rigid plastic packaging market niches in each country where it has a presence. In Thailand, it focuses on rigid packaging for the food & specialty beverages, pharmaceuticals, and home care industries, for which it estimates an aggregate market size of US\$401m in 2022 and forecasts a 2023-28 CAGR of 4.0% to US\$507m in 2028. TPAC has about a 14% mean market share of its industry niches in Thailand. In India, it focuses on rigid packaging for the food & specialty beverages and pharmaceuticals industries, for which it estimates a market size of \$1,363m in 2022 and forecasts a 2023-28 CAGR of 10.7% to \$2,509m in 2028. TPAC's mean market share across its industry niches in India is about 7%.

In the UAE, the firm focuses on rigid packaging for the food and cosmetics & personal care industries, for which it estimates an aggregate market size at \$44m in 2022 and forecasts a 2023-28 CAGR of 5.0% to \$59m in 2028. TPAC has a mean market share of about 40% of these niches in the UAE. In Malaysia, it focuses on rigid packaging for the food industry, for which it estimates a market size of \$40m and forecasts a 2023-28 CAGR of 6.0% to \$57m in 2028. TPAC's market share of rigid food packaging in Malaysia is about 75%.

Figure 2 : TPAC's 1Q23 sales breakdown, by geography



Source: Company data



Sources: Company data, Bualuang Research

2028E

2022

TPAC 5

share, 75%



These markets—Thailand, India, the UAE, and Malaysia—are all expanding fairly quickly, so we see substantial growth opportunities for TPAC. The firm plans to expand its market shares of rigid plastic packaging in these countries through organic and inorganic expansion, new product development, and by building its customer base. Our sensitivity analysis suggests that every 1% increase in its mean market share would add 7% to our 2024 earnings forecast and an average of 5% to our long-term projections. Apart from rigid plastic packaging, TPAC has expanded its product range to paper packaging for the food industry.


Figure 4 : Sensitivity analysis of effect of changes in TPAC's market share on our profit forecasts

Change in market share						
Base case	+1%	+2%	+3%			
604	642	682	722			
	7%	13%	20%			
		Base case +1% 604 642	Base case +1% +2% 604 642 682	Base case +1% +2% +3% 604 642 682 722		

Source: Bualuang Research estimates

Expansive earnings profile with a strong balance sheet: Similarly to many other companies that operate in multiple jurisdictions, TPAC encountered cost inflation pressures in 2022, which squeezed its gross margin. GM was slimmest in 2Q22, then recovered QoQ, 3Q22-1Q23. The GM expansion drivers were procurement cost savings and the company's ability to pass through cost increases to customers. Despite a slimmer gross margin, TPAC still delivered YoY core profit growth for 2022, led by top-line expansion, underpinned by organic volume growth, a contribution by Skypet India (acquired on April 1, 2022), and the full-year consolidation of Combi-Pack Malaysia.

Premised on greater sales volume to be brought about by broadly improving demand, a fullyear contribution by Skypet, and a fatter GM (easing cost pressures), we expect TPAC to deliver 2023 core earnings of Bt522m, spectacular YoY growth of 75.7%. Looking further ahead, our model points to a 2024-25 core profit CAGR of 10.6%. And there's scope for upside to our revenue and earnings projections from new investments—greenfield and acquisitions.



300 200 16 5% 100 0 2021 2022 2023E 2024E 2025E 2025E 2021 2022 2023E 2024E Sources: Company data, Bualuang Research estimates

TPAC 6

BUALUANG SECURITIES

TPAC's balance sheet looks set to remain strong going forward. Due to debt-financing for an asset acquisition in 2021, its net debt/equity ratio rose from 1.1x at YE21 to 1.2x at YE22 (still far below its creditor covenant of 2.0x). From there, its net debt/equity ratio will gradually decline, due to debt repayment and greater equity (generated by rising earnings). We project an EBITDA CAGR of 7.1% for 2024-25. Hence, the company should have ample debt headroom to fund future organic investments and acquisitions.




Figure 6 : TPAC's net debt/equity ratio, YE21-25E

Valuation and recommendation

BUY to a YE23 DCF-derived target price of Bt22: We have re-initiated coverage on TPAC with a BUY call. In order to determine its value, we applied the discounted cashflow (DCF) approach (as TPAC generates steady cashflows from business operations) to arrive at a YE23 target price of Bt22 (WACC of 10.5%, terminal growth rate of 2.0%).

We expect the company to deliver superior earnings growth through 2025. But the market hasn't yet anticipated or priced in its rapid profit growth expansion profile, we believe. The stock currently trades at low valuation metrics compared with its peers—a 2023 PER of only 10.3x (a 47% discount to the peer mean of 19.6x), a YE23 PBV of 1.8x (35% below the peer mean PBV of 2.7x), and a 2023 EV/EBITDA ratio of 6.3x (45% below the peer mean of 11.4x).

Sources: Company data, Bualuang Research estimates



Figure 7 : TPAC looks set to deliver superior financial performances, but the stock trades at deep valuation discounts to its peers								
	APTAR	AMCOR	SFLEX	SCGP	TPAC			
	Aptar 🖌	🔇 amcor		SCGP				
Financial summary								
Core EPS growth (2023E)	12.3%	-9.8%	218.6%	9.0%	75.8%			
EBITDA margin (2023E)	19.2%	13.5%	12.3%	13.9%	18.2%			
ROE (2023E)	13.5%	26.8%	17.7%	6.2%	19.8%			
Valuation summary								
PER (x) (2023E)	28.0	13.8	19.3	26.5	10.3			
PEG (x) (2023E)	1.9	2.6	1.0	4.0	1.0			
PBV (x) (2023E)	3.5	3.6	3.2	1.7	1.8			
PBV/ROE (x) (2023E)	0.3	0.1	0.2	0.3	0.1			
EV/EBITDA (x) (2023E)	13.4	10.8	15.5	11.1	6.3			

Source: Bloomberg, Bualuang Research estimates

• •

Regional Comparisons

Bloomberg	Price	Market Cap	PER	PER (x) EPS Growth (%)		PBV (x)		ROE (%)		Div Yield (%)		
0 - 1 -	(1	(US\$	0000F	00045	0000F	00045	0000F	00045	00005	00045	00005	00045
Code	(local curr.)	equivalent)	2023E	2024E	2023E	2024E	2023E	2024E	2023E	2024E	2023E	2024E
PKG US	USD136.0	12,229	16.6	17.0	-26.2	-2.2	3.3	3.1	19.6	18.6	3.7	3.6
IP US	USD31.6	10,970	14.7	16.5	-45.7	-16.2	1.3	1.3	8.5	6.5	5.8	5.9
GPK US	USD23.8	7,313	8.1	8.0	62.9	1.1	2.6	2.0	35.0	27.0	1.6	4.7
WRK US	USD30.4	7,774	12.3	12.7	-239.5	-149.9	0.8	0.7	5.7	6.8	3.6	3.7
SON US	USD58.4	5,721	10.3	9.9	12.7	2.3	2.4	2.1	24.8	22.5	3.5	3.6
BERY US	USD66.6	7,941	9.0	8.1	26.1	11.2	2.4	2.1	25.5	25.5	1.5	1.3
SLGN US	USD47.8	5,269	12.1	11.2	27.5	7.6	2.7	2.3	22.5	20.0	1.5	1.5
MYE US	USD19.8	728	11.9	10.9	-1.8	9.8	2.4	2.1	22.7	21.4	2.7	2.7
SEE US	USD46.0	6,636	13.4	11.6	-5.4	23.4	10.0	5.9	93.6	62.8	1.8	1.8
CCK US	USD91.5	10,994	14.5	12.6	-12.7	17.8	4.6	4.1	32.5	32.8	0.8	0.8
ATR US	USD119.3	7,819	28.0	24.6	16.3	14.0	3.5	3.3	13.5	15.3	1.3	1.4
WPK CN	CAD41.1	2,026	13.6	13.4	16.1	2.0	1.5	1.4	11.3	10.3	0.3	0.3
CCL/B CN	CAD65.1	8,772	17.5	16.5	6.3	5.4	2.4	2.2	14.9	14.3	1.6	1.8
SCGP TB	THB38.25	4,800	26.2	21.2	7.9	23.7	1.3	1.2	6.3	7.5	1.7	2.1
SFLEX TB	THB4.24	98	18.7	14.1	238.0	32.2	3.1	2.6	17.6	20.1	2.4	3.2
TPAC TB	THB16.50	158	10.3	8.9	63.6	15.8	1.8	1.6	21.5	21.1	2.9	3.4
			14.8	13.6	9.1	-0.1	2.9	2.4	23.5	20.8	2.3	2.6
	Code PKG US IP US GPK US WRK US SON US BERY US SLGN US SLGN US MYE US SEE US CCK US ATR US WPK CN CCL/B CN SCGP TB SFLEX TB TPAC TB	Code(local curr.)PKG USUSD136.0IP USUSD31.6GPK USUSD23.8WRK USUSD30.4SON USUSD58.4BERY USUSD66.6SLGN USUSD47.8MYE USUSD19.8SEE USUSD47.8MYE USUSD19.8SEE USUSD46.0CCK USUSD19.5ATR USUSD119.3WPK CNCAD41.1CCL/B CNCAD65.1SCGP TBTHB38.25SFLEX TBTHB4.24	(US\$ Code (local curr.) equivalent) PKG US USD136.0 12,229 IP US USD31.6 10,970 GPK US USD23.8 7,313 WRK US USD30.4 7,774 SON US USD58.4 5,721 BERY US USD66.6 7,941 SLGN US USD47.8 5,269 MYE US USD19.8 728 SEE US USD46.0 6,636 CCK US USD91.5 10,994 ATR US USD119.3 7,819 WPK CN CAD41.1 2,026 CCL/B CN CAD65.1 8,772 SCGP TB THB38.25 4,800 SFLEX TB THB4.24 98 TPAC TB THB16.50 158	(US\$ equivalent) 2023E PKG US USD136.0 12,229 16.6 IP US USD31.6 10,970 14.7 GPK US USD23.8 7,313 8.1 WRK US USD30.4 7,774 12.3 SON US USD58.4 5,721 10.3 BERY US USD47.8 5,269 12.1 MYE US USD19.8 728 11.9 SEE US USD46.0 6,636 13.4 CCK US USD119.3 7,819 28.0 WPK CN CAD41.1 2,026 13.6 CCL/B CN CAD65.1 8,772 17.5 SCGP TB THB38.25 4,800 26.2 SFLEX TB THB4.24 98 18.7 TPAC TB THB16.50 158 10.3	(US\$) code (local curr.) equivalent) 2023E 2024E PKG US USD136.0 12,229 16.6 17.0 IP US USD31.6 10,970 14.7 16.5 GPK US USD23.8 7,313 8.1 8.0 WRK US USD30.4 7,774 12.3 12.7 SON US USD58.4 5,721 10.3 9.9 BERY US USD66.6 7,941 9.0 8.1 SLGN US USD47.8 5,269 12.1 11.2 MYE US USD19.8 728 11.9 10.9 SEE US USD46.0 6,636 13.4 11.6 CCK US USD119.3 7,819 28.0 24.6 WPK CN CAD41.1 2,026 13.6 13.4 CCL/B CN CAD65.1 8,772 17.5 16.5 SCGP TB THB3.25 4,800 26.2 21.2 SFLEX TB THB4.24 98 18.7 14.1	(US\$ code (local curr.) equivalent) 2023E 2024E 2023E PKG US USD136.0 12,229 16.6 17.0 -26.2 IP US USD31.6 10,970 14.7 16.5 -45.7 GPK US USD23.8 7,313 8.1 8.0 62.9 WRK US USD30.4 7,774 12.3 12.7 -239.5 SON US USD58.4 5,721 10.3 9.9 12.7 BERY US USD66.6 7,941 9.0 8.1 26.1 SLGN US USD47.8 5,269 12.1 11.2 27.5 MYE US USD19.8 728 11.9 10.9 -1.8 SEE US USD40.0 6,636 13.4 11.6 -5.4 CCK US USD119.3 7,819 28.0 24.6 16.3 WPK CN CAD41.1 2,026 13.6 13.4 16.1 CCL/B CN CAD65.1 8,772 17.5 16.5 6	(US\$ 2023E 2024E 2023E 2024E PKG US USD136.0 12,229 16.6 17.0 -26.2 -2.2 IP US USD31.6 10,970 14.7 16.5 -45.7 -16.2 GPK US USD33.8 7,313 8.1 8.0 62.9 1.1 WRK US USD30.4 7,774 12.3 12.7 -239.5 -149.9 SON US USD58.4 5,721 10.3 9.9 12.7 2.3 BERY US USD66.6 7,941 9.0 8.1 26.1 11.2 SLGN US USD47.8 5,269 12.1 11.2 27.5 7.6 MYE US USD46.0 6,636 13.4 11.6 -5.4 23.4 CCK US USD91.5 10,994 14.5 12.6 -12.7 17.8 ATR US USD119.3 7,819 28.0 24.6 16.3 14.0 WPK CN CAD41.1 2,026 13.6	Code (local curr.) equivalent) 2023E 2024E 203E	US\$ 2023E 2024E 2023E 2023E 2023E 2023E 2023E 2	Code (lOsal curr.) equivalent) 2023E 2024E 203E 2024E 203E 2024E 203E 2024E 2023E 2024E 2025	Code (local curr.) equivalent) 2023E 2024E 2023E 2023E 2023E <td>Code (Iocal curr.) equivalent) 2023E 2024E 2023E 203E IP US USD31.6 10,970 14.7 16.5 -45.7 -16.2 1.3 1.3 8.5 6.5 5.8 SON US USD30.4 7,774 12.3 12.7 -2.3 2.4 2.1 2.5 2.5</td>	Code (Iocal curr.) equivalent) 2023E 2024E 2023E 203E IP US USD31.6 10,970 14.7 16.5 -45.7 -16.2 1.3 1.3 8.5 6.5 5.8 SON US USD30.4 7,774 12.3 12.7 -2.3 2.4 2.1 2.5 2.5

PER band versus SD (next 12 months)



PBV band versus SD (next 12 months) х 3.5 3.0 +2.0 SD = 2.63x 2.5 +1.0 SD = 2.22x 2.0 LT-average = 1.81x -1.0 SD = 1.40x 1.5 -2.0 SD = 0.99x 1.0 0.5

YE20-


YE21-

YE22-

YE234




PER band and share price




PBV band and share price

YE19-



Foreign holdings



YE24



Bualuang Securities Public Company Limited

DISCLAIMER

BUALUANG SECURITIES PUBLIC COMPANY LIMITED (BLS) is a subsidiary of BANGKOK BANK PUBLIC COMPANY LIMITED (BBL). This document is produced based upon sources believed to be reliable but their accuracy, completeness or correctness is not guaranteed. The statements or expressions of opinion herein were arrived at after due and careful consideration to use as information for investment. Expressions of opinion contained herein are subject to change without notice. This document is not, and should not be construed as, an offer or the solicitation of an offer to buy or sell any securities. The use of any information shall be at the sole discretion and risk of the user.

BUALUANG SECURITIES PUBLIC COMPANY LIMITED MAY BE IN RELATIONSHIP WITH THE SECURITIES IN THIS REPORT. "Opinions, projections and other information contained in this report are based upon sources believed to be accurate including the draft prospectus, but no responsibility is accepted for any loss occasioned by reliance placed upon the contents hereof. Bualuang Securities Public Company Limited may from time to time perform investment, advisory or other services for companies mentioned in this report, as well as dealing (as principal or otherwise) in, or otherwise being interested in, any securities mentioned herein, This report does not constitute a solicitation to buy or sell any securities". Investors should carefully read details in the prospectus before making investment decision.

BUALUANG SECURITIES PUBLIC COMPANY LIMITED MAY ACT AS MARKET MAKER AND ISSUER OF DWs, AND ISSUER OF STRUCTURED NOTES ON THESE SECURITIES. The company may prepare the research reports on those underlying securities. Investors should carefully read the details of the derivative warrants and structured notes in the prospectus before making investment decisions.

ADVANC	AMATA	AOT	BDMS	BH	CBG	CENTEL	CPALL	GLOBAL	GPSC	IRPC	KBANK	KCE	KTC	MINT
PTG	PTT	PTTEP	PTTGC	SCB	SPRC	TOP	WHA	STA	BGRIM	GULF	MTC	AWC	CRC	CPF
CPN	HANA	HMPRO	NL	OSP	SAWAD	BANPU	BCH	BTS	SCC	τυ	INTUCH	VGI	SCGP	COM7
DOHOME	JMT	CHG	TTB	BAM	BCP	AP	KTB	KKP	OR	BEM	GUNKUL	EA	RBF	STGT
JMART	BEC	KEX	RCL	SINGER	TIDLOR	FORTH	AAV	DELTA	SABUY	CKP	TRUE	PSL	SIRI	TQM
CK	ERW	MEGA	SNNP	TLI										

BUALUANG SECURITIES PUBLIC COMPANY LIMITED IS OR MAY BE AN UNDERWRITER/CO-UNDERWRITER/JOINT LEAD IN RESPECT OF THE INITIAL PUBLIC OFFERING (IPO) OF SECURITIES.

Financial Advisor	Lead underwriter/ Underwriter/ Co-underwriter
	ксд

CG Rating

Score Range	Score Range	Description
90 - 100		Excellent
80 – 89		Very Good
70 – 79		Good
60 - 69		Satisfactory
50 – 59		Pass
Below 50	No logo given	N/A

Thailand's Private Sector Collective Action Coalition Against Corruption programme (Thai CAC) under Thai Institute of Directors

- companies that have **declared** their intention to join CAC, and
- companies certified by CAC.



CORPORATE GOVERNANCE REPORT DISCLAIMER

This research report was prepared by Bualuang Securities Public Company Limited and refers to research prepared by Morgan Stanley. Morgan Stanley does not warrant or guarantee the accuracy or completeness of its research reports. Morgan Stanley reserves copyright and other proprietary rights in the material reproduced in this report. Morgan Stanley is under no obligation to inform Bualuang Securities or you if the views or information referred to or reproduced in this research report change.

Corporate Governance Report disclaimer

The disclosure of the survey result of the Thai Institute of Directors Association (IOD) regarding corporate governance is made pursuant to the policy of the Office of the Securities and Exchange Commission. The IOD survey is based on the information of a company listed on the Stock Exchange of Thailand and the Market for Alternative Investment disclosed to the public and able to be accessed by a general public investor. The result, therefore, is from the perspective of a third party. It is not an evaluation of operation and is not based on inside information.

The survey result is as of the date appearing in the Corporate Governance Report of Thai Listed Companies. As a result, the survey result may be changed after that date. Bualuang Securities Public Company Limited neither confirms nor certifies the accuracy of such survey results.

"Disclaimer: The disclosure of the Anti-Corruption Progress Indicators of a listed company on the Stock Exchange of Thailand, which is assessed by the relevant institution as disclosed by the Office of the Securities and Exchange Commission, is made in order to comply with the policy and sustainable development plan for the listed companies. The relevant institution made this assessment based on the information received from the listed company, as stipulated in the form for the assessment of Anti-corruption which refers to the Annual Registration Statement (Form 56-1), Annual Report (Form 56-2), or other relevant documents or reports of such listed company. The assessment result is therefore made from the perspective of a third party. It is not an assessment of operation and is not based on any inside information. Since this assessment is only the assessment result as of the date appearing in the assessment result, it may be changed after that date or when there is any change to the relevant information. Nevertheless, Bualuang Securities Public Company Limited neither confirms, verifies, nor certifies the accuracy and completeness of the assessment result."

BUALUANG RESEARCH – RECOMMENDATION FRAMEWORK

STOCK RECOMMENDATIONS

BUY: Expected positive total returns of 15% or more over the next 12 months.

HOLD: Expected total returns of between -15% and +15% over the next 12 months.

SELL: Expected negative total returns of 15% or more over the next 12 months.

TRADING BUY: Expected positive total returns of 15% or more over the next 3 months.

SECTOR RECOMMENDATIONS

OVERWEIGHT: The industry, as defined by the analyst's coverage universe, is expected to outperform the relevant primary market index over the next 12 months. **NEUTRAL:** The industry, as defined by the analyst's coverage universe, is expected to perform in line with the relevant primary market index over the next 12 months.

UNDERWEIGHT: The industry, as defined by the analyst's coverage universe, is expected to underperform the relevant primary market index over the next 12 months.



IMPORTANT DISCLOSURES FOR U.S. PERSONS

This research report was prepared by Bualuang Securities Public Company Limited ("BLS"). BLS is not a registered broker-dealer in the United States and, therefore, is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. This research report is provided for distribution to "major U.S. institutional investors" in reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act").

Under no circumstances should any recipient of this research report effect any transaction to buy or sell securities or related financial instruments through BLS. Rosenblatt Securities Inc. accepts responsibility for the contents of this research report, subject to the terms set out below, to the extent that it is delivered to a U.S. person other than a major U.S. institutional investor.

The analyst whose name appears in this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA") and may not be an associated person of Rosenblatt Securities Inc. and, therefore, may not be subject to applicable restrictions under FINRA Rules on communications with a subject company, public appearances and trading securities held by a research analyst account.

Additional Disclosures

This research report is for distribution only under such circumstances as may be permitted by applicable law. This research report has no regard to the specific investment objectives, financial situation or particular needs of any specific recipient, even if sent only to a single recipient. This research report is not guaranteed to be a complete statement or summary of any securities, markets, reports or developments referred to in this research report. Neither BLS nor any of its directors, officers, employees or agents shall have any liability, however arising, for any error, inaccuracy or incompleteness of fact or opinion in this research report or lack of care in this research report's preparation or publication, or any losses or damages which may arise from the use of this research report.

BLS may rely on information barriers, such as "Chinese Walls" to control the flow of information within the areas, units, divisions, groups, or affiliates of BLS.

Investing in any non-U.S. securities or related financial instruments (including ADRs) discussed in this research report may present certain risks. The securities of non-U.S. issuers may not be registered with, or be subject to the regulations of, the U.S. Securities and Exchange Commission. Information on such non-U.S. securities or related financial instruments may be limited. Foreign companies may not be subject to audit and reporting standards and regulatory requirements comparable to those in effect within the United States.

The value of any investment or income from any securities or related financial instruments discussed in this research report denominated in a currency other than U.S. dollars is subject to exchange rate fluctuations that may have a positive or adverse effect on the value of or income from such securities or related financial instruments.

Past performance is not necessarily a guide to future performance and no representation or warranty, express or implied, is made by BLS with respect to future performance. Income from investments may fluctuate. The price or value of the investments to which this research report relates, either directly or indirectly, may fall or rise against the interest of investors. Any recommendation or opinion contained in this research report may become outdated as a consequence of changes in the environment in which the issuer of the securities under analysis operates, in addition to changes in the estimates and forecasts, assumptions and valuation methodology used herein.

No part of the content of this research report may be copied, forwarded or duplicated in any form or by any means without the prior consent of BLS and BLS accepts no liability whatsoever for the actions of third parties in this respect.